

## SPECIALTY GUIDELINE MANAGEMENT

### TIKOSYN (dofetilide) dofetilide (generic)

#### POLICY

##### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

###### A. FDA-Approved Indications

1. Maintenance of normal sinus rhythm (delay in time to recurrence of atrial flutter/atrial fibrillation [AF/AFI]) in patients with AF/AFI of greater than one week duration who have been converted to normal sinus rhythm
2. Conversion of AF/AFI to normal sinus rhythm

###### B. Compendial Uses

1. Supraventricular tachycardia
2. Ventricular tachyarrhythmia

All other indications are considered experimental/investigational and not medically necessary.

##### II. CRITERIA FOR APPROVAL

###### 1. **Atrial Flutter/Atrial fibrillation**

Authorization of 12 months may be granted for the maintenance of, or conversion to, normal sinus rhythm after atrial flutter or atrial fibrillation.

###### 2. **Supraventricular tachycardia**

Authorization of 12 months may be granted for treatment and prevention of supraventricular tachycardia.

###### 3. **Ventricular tachyarrhythmia**

Authorization of 12 months may be granted for treatment and prevention of ventricular tachyarrhythmia.

##### III. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet ALL initial authorization criteria.

##### IV. REFERENCES

1. Tikosyn [package insert]. New York, NY: Pfizer Inc.; August 2019.
2. Dofetilide [package insert]. East Windsor, NJ: Aurobindo Pharma USA, Inc.; September 2019.
3. Micromedex Solutions [database online]. Cambridge, MA: IBM Watson Health. Updated periodically. [www.micromedexsolutions.com](http://www.micromedexsolutions.com) [available with subscription]. Accessed April 9, 2020.

Reference number(s)
1873-A

4. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016;67(13).